TerminatedPHASE1, PHASE2NCT02495103
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Studying Hereditary clear cell renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Ramaprasad Srinivasan, M.D.National Cancer Institute (NCI)
- Intervention
- Vandetanib(drug)
- Enrollment
- 7 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2020
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02495103 on ClinicalTrials.govOther trials for Hereditary clear cell renal cell carcinoma
Additional recruiting or active studies for the same condition.
See all trials for Hereditary clear cell renal cell carcinoma →